ReviewDiscover oncology2026
Oncogenic signaling pathways in ameloblastoma and their implications for precision based therapy.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ameloblastoma is an odontogenic epithelial tumor characterized by a paradoxical clinical behavior. Although histologically benign and typically non-metastatic, it demonstrates aggressive local growth, extensive bone destruction, and a high propensity for recurrence. Surgical resection remains the primary treatment modality but is frequently associated with significant functional and aesthetic morbidity, highlighting the need for alternative, biology-driven therapeutic approaches. Advances in molecular profiling have revealed that ameloblastoma is driven by recurrent, highly specific oncogenic alterations rather than generalized genomic instability. Constitutive activation of the mitogen-activated protein kinase (MAPK) pathway-most commonly through BRAF V600E mutations and particularly prominent in mandibular ameloblastomas-represents the principal oncogenic mechanism in a major molecular subset, with additional involvement of FGFR2 and Hedgehog signaling in distinct subgroups. These pathways, which are key regulators of odontogenic development, confer strong oncogenic pathway dependency while maintaining a developmentally constrained tumor phenotype. Accumulating clinical evidence indicates that pathway-directed therapies, particularly combined BRAF and MEK inhibition, can induce rapid and durable responses in patients with locally advanced, recurrent, or metastatic ameloblastoma. Targeted therapy has also demonstrated potential roles in neoadjuvant tumor downstaging and long-term disease control, enabling surgical de-escalation in selected cases. Emerging strategies targeting FGFR, Hedgehog, epigenetic regulators, and PI3K signaling remain investigational but highlight additional therapeutic vulnerabilities. The objective of this review is to summarize current molecular and clinical evidence supporting pathway-directed targeted therapy in ameloblastoma and to explore its implications for precision-based treatment strategies beyond traditional surgical management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.